Your search for non small cell lung cancer returned 5 results

Cancer patients with biomarker-positive tumors have better outcomes on immune checkpoint inhibitor therapy, a meta-analysis suggests.

A regulatory decision is expected on November 27, 2023.

Improvement seen compared with chemotherapy alone for first-line treatment of advanced non-small cell lung cancer.

Amivantamab can provide a long-term benefit in NSCLC patients with EGFR exon 20 insertions whose disease progressed on platinum-based chemotherapy, a study suggests.

Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody.